Hybrid and decentralized clinical trials (DCTs) are fast becoming the norm, but they often involve multiple vendors and service providers, presenting sponsors and CROs with new considerations on the logistics of study conduct. By leveraging the expertise of their vendors, sponsors and contract research organizations (CROs) can avoid common pitfalls that can contribute to inefficiencies, safety concerns, and increased costs.
Read the Drug Discovery World article by Stephanie Larimer, IQVIA Laboratories, Decentralized Trials Solutions Manager and Tom Brazier, mdgroup, Decentralized Clinical Solutions Director, as they shared their insights and opportunities for decentralized clinical trials and how common pitfalls can be avoided through communications and streamlined working.
Read the article
Related Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Biorepository and Specimen Management
Your biological specimens are irreplaceable assets – trust them with a proven partner
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
Helping you master your lab data
Improved oversight with your lab data now in full view
NASH and Liver Disease Capabilities
Nonalcoholic Fatty Liver Diseases & Non-alcoholic Steatohepatitis (NAFLD & NASH)
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Pediatric Initiative
Optimizing small blood volumes to prevent canceled tests in clinical trials for pediatric patients
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021
